Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

filgotinib maleate

JYSELECA

filgotinib maleate (JYSELECA) is a tyrosine-protein kinase jak2 inhibitor.

PMDA: approved
Patents linked 6
Pipeline programs 8
News articles 0
Drug details — filgotinib maleate
Class
—
Route
—
Patents
6
Programs
8
Data quality
0.78
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

filgotinib maleate (JYSELECA) is a tyrosine-protein kinase jak2 inhibitor.

Key facts

INN filgotinib maleate
Brand JYSELECA
Mechanism Tyrosine-protein kinase JAK2 inhibitor
Target Tyrosine-protein kinase JAK1

Mechanism of action

Tyrosine-protein kinase JAK2 inhibitor

Primary target: Tyrosine-protein kinase JAK1

Approval history

Authority Status Date
PMDA approved —

Pipeline programs

Browse pipeline
  1. GLPG0634-CL-329 Phase 3 · Alfasigma · Polyarticular-course juvenile idiopathic arthritis
  2. GLPG0634-CL-331 Phase 3 · Alfasigma · Ulcerative colitis
  3. GLPG0634-CL-333 Phase 3 · Alfasigma · Juvenile idiopathic arthritis
  4. GS-US-417-0304 Phase 3 · Alfasigma · Rheumatoid arthritis
  5. GS-US-418-3899 Phase 3 · Alfasigma · Ulcerative Colitis (UC)
  6. GLPG-0634-CL-131 Phase 1 · Alfasigma · juvenile idiopathic arthritis
  7. 2024-517112-30-00 Approved · Disc Medicine · Rheumatoid arthritis
  8. PRIMERA001 Approved · Disc Medicine · Rheumatoid arthritis according to 2010 criteria

Related & competitor drugs

Browse all drugs
  1. abrocitinib Dermatologicals (D11)
  2. baricitinib Antineoplastic and immunomodulating agents (L04)
  3. deuruxolitinib phosphate Tyrosine-protein kinase JAK1 inhibitor
  4. ruxolitinib phosphate Tyrosine-protein kinase JAK2 inhibitor
  5. filgotinib Antineoplastic and immunomodulating agents (L04)
  6. momelotinib Tyrosine-protein kinase JAK1 inhibitor

Related patents

Browse patents

  1. IT 202300012522

    FLUOROMETIL-CARNITINA PER USO COME INIBITORE DI COLINA TRIMETILAMMINA (TMA) LIASI.

    Expires Sat Dec 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. AU 2023257308

    USES OF FARNESOID X RECEPTOR AGONISTS

    Expires Wed Oct 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. CA 3263063

    VELUSETRAG DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE LA PSEUDO-OBSTRUCTION INTESTINALE CHRONIQUE (POIC)

    Expires Wed Mar 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. CA 3222905

    UTILISATION DE SOUCHES BACTERIENNES DE LACTOBACILLUS PARACASEI DANS LE TRAITEMENT DE NOUVEAU-NES

    Expires Wed Jan 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. EP 3986378

    PHARMAZEUTISCHE ZUSAMMENSETZUNGEN IN FORM VON GEL MIT XYLOGLUCAN UND ALKOHOLEN ZUR KONTROLLIERTEN FREISETZUNG VON WIRKSTOFFEN

    Expires Tue Apr 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. WO 2019180199

    COMPOSITION AQUEUSE STABLE DE PHOSPHOCRÉATINE

    Expires Wed Sep 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is filgotinib maleate?

filgotinib maleate (JYSELECA) is a tyrosine-protein kinase jak2 inhibitor.

What is the brand name for filgotinib maleate?

JYSELECA is a marketed brand name for filgotinib maleate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.